



Protein Synthesis Inhibitors


Pharmacology and Toxicology General Pharmacology Second Year Medical Students Tareq Saleh Faculty of Medicine The Hashemite University Textbook: Chapter 30 pp: 384-399








Bacterial Protein Synthesis
























Tetracycline

TETRACYCLINES

Demeclocycline DECLOMYCIN Doxycycline VIBRAMYCIN Minocycline MINOCIN Tetracycline








Mechanism of action

-bind *reversibly* to the **30S** subunit of bacterial ribosomes

-prevent the binding of tRNA to the mRNAribosome complex









Antibacterial spectrum

- Bacteriostatic
- Effective against gram-positive, gram-negative, protozoa, spirochetes, atypical, etc

Commonly used for the treatment of:


- 1. Acne (doxycycline)
- 2. Chlamydia (doxycycline)
- 3. Peptic ulcer disease (tetracycline)
- 4. Lyme Disease (doxycycline)
- 5. Mycoplasma Pneumonia (doxycycline)







Therapeutic Spectrum of Doxycycline










Mechanisms of resistance

- Efflux pump (most common)
- Enzymatic inactivation of the drug
- Interfering with binding to ribosomes
- Cross-resistance is not common










Pharmacokinetics

Absorption

- Oral
- Adequately absorbed
- ↓ absorption when administered with dairy (high cations) → formation of nonabsorbable chelates










Pharmacokinetics

Distribution

- Distribute well in body fluids, including CSF
- Bind to tissues undergoing calcification e.g., bones, teeth.
- Cross placenta and deposit in fetal bones

Elimination

- Tetracycline eliminated unchanged in urine
- Doxycycline eliminated in bile/feces









Adverse effects

- Gastric discomfort:
- -irritation of gastric mucosa-esophagitis
- Effects on calcified tissues
- -deposited in tissues undergoing calcification, e.g., bones in children.
- -dental hypoplasia
- -growth problems
- -pediatric use is limited





Gl disturbance

Deposition of drug in bones and teeth









Adverse effects

- Hepatotoxicity
- Phototoxicity:
- -severe sunburns (recommended to wear sun protection)
- Vestibular dysfunction:
- -dizziness, vertigo, tinnitus
- Pseudotumor cerebri









Contraindications

- 1. Pregnant women
- 2. Breast-feeding women
- 3. Pediatric age group <8 years







Glycylcyclines








Tigecycline

- Derivative of minocycline
- Same mechanism of action as tetracyclines
- Similar mechanisms of resistance









Tigecycline


Antibacterial spectrum

- Effective against MRSA
- Effective against multi-drug resistant streptococci
- Effective against vancomycin-resistant enterococci (VRE)
- Effective against ESBL gram-negative bacteria
- Effective against Acinetobacter spp
- NOT effective against Pseudomonas


















AMINOGLYCOSIDES

Amikacin Gentamicin GARAMYCIN Neomycin NEO-FRADIN Streptomycin Tobramycin TOBREX








Mechanism of action

- Bind to 30S ribosomal subunit
- Interfere with assembly of the functional ribosomal apparatus
- Cause the 30S subunit of the completed ribosome to misread the genetic code









Antibacterial spectrum

- Bactericidal
- Concentration-dependent
- Exhibit PAE
- Effective against gram-negative bacilli (INCLUDING multi-DRUG resistant *P. aeruginosa*)
- \bullet Used in combination with $\beta\mbox{-lactams}$







- Tularemia is acquired during rabbithunting season by hunters skinning infected animals.
- Pneumonic tularemia results from infection by the respiratory route or by bacteremic seeding of lungs.
- Gentamicin is effective in treating this rare lymphoid disease.

SYNERGY

 Aminoglycosides may be added to β-lactams for synergy for select serious gram-positive infections.

Gram (+) cocci


Enterococcus species (ampicillin + gentamicin)

<u>Streptococcus agalactiae</u> (ampicillin + gentamicin)


Gram (+) bacilli Gram (-) cocci

Gram (–) rods

- Acinetobacter baumannii
- Brucella species (gentamicin + doxycydine)



Some clinical uses of aminoglycosides











Mechanisms of resistance

- 1) efflux pumps
- 2) decreased uptake
- 3) modification and inactivation by plasmid-associated synthesis of enzymes that hydrolyze aminoglycosides

-Amikacin is less vulnerable to these enzymes







Pharmacokinetics


Absorption

-all are given IV (except neomycin)

Distribution

12/7/2023

- -variable distribution in body fluids
- -inadequate distribution in CSF
- -cross the placenta










Pharmacokinetics

Elimination

- -90% are excreted unchanged in the urine
- -accumulation occurs in cases of renal dysfunction










Adverse effects

- Ototoxicity (vestibular and auditory)
- -might cause irreversible deafness
- -Vertigo (especially with streptomycin)
- Nephrotoxicity
- -disrupt Ca⁺⁺-mediated transport processes
- -from mild reversible renal impairment to irreversible acute tubular necrosis

Ototoxicity Nephrotoxicity









Adverse effects

- Neuromuscular paralysis
- -patient with myasthenia gravis are at risk
- Allergic reaction
- Mostly contact dermatitis with topical neomycin

Paralysis

Skin rash
















MACROLIDES/KETOLIDES

Azithromycin ZITHROMAX Clarithromycin BIAXIN Erythromycin various Telithromycin KETEK








Mechanism of action

- bind *irreversibly* to a site on the 50S subunit of the bacterial ribosome
- Inhibit translocation step
- Interfere with transpeptidation
- Binding site identical/near that of clindamycin or chloramphenicol









Antibacterial spectrum

-bacteriostatic (can be -cidal at high doses)

• Erythromycin

-similar spectrum to penicillin G

-used in cases of penicillin allergy

Clarithromycin

-similar to erythromycin

-effective against intracellular pathogens, e.g. Chlamydia, Legionella, H. Pylori etc...







Antibacterial spectrum


- Azithromycin
- -less active against staph and strep species
- -more active against RTI due to *H. influenzae* or *M.catarrhalis*
- -increasing S. pneumonia resistance







Clinical Spectrum of Macrolides









Mechanisms of resistance

- 1) the inability of the organism to take up the antibiotic
- 2) the presence of efflux pumps
- 3) a decreased affinity of the 50S ribosomal subunit for the antibiotic
- 4) the presence of plasmid- associated erythromycin esterases in gram-negative organisms








Pharmacokinetics

- Administration
- oral (enteric-coated tablets for erythro)
- Erythro and azithro are available IV
- Distribution
- -distribute well in body fluids except CSF

• Elimination

- -hepatic metabolism
- -Inhibit CYP450 system (drug-drug interactions)









Pharmacokinetics

- Administration
- oral (enteric-coated tablets for erythro)
- Erythro and azithro are available IV
- Distribution
- -distribute well in body fluids except CSF

• Elimination

-hepatic metabolism

-Inhibit CYP450 system (drug-drug interactions)

	Erythro- mycin	Clarithro- mycin	Azithro- mycin	Telithro- mycin
Oral absorption	Yes	Yes	Yes	Yes
Half-life (hours)	2	3.5	>40	10
Conversion to an active metabolite	No	Yes	No	Yes
Percent excretion in urine	15	50	12	13








Macrolides and Ketolides

Drug-drug interactions

 Inhibit hepatic metabolism of a number of drugs







Macrolides and Ketolides


Adverse effects

Gastric distress and motility

-high doses of erythromycin cause smooth muscle contraction and bowel movement. Could this be helpful?

- Jaundice
- Ototoxicity
- Hepatotoxicity

-contraindicated in patients with hepatic dysfunction







Fidaxomicin







Fidaxomicin

- Structure: macrocyclic, similar to macrolides
- MOA: acts on the σ subunit of RNA polymerase \rightarrow disruption of bacterial transcription \rightarrow \bigcirc protein synthesis
- Very narrow-spectrum: gram-positive aerobes/anaerobes
- Poorly absorbed (remains in GI tract), primarily used for C. difficile infections
- Cross-resistance with other antibiotics is rare. Why?
- Cross-allergy with macrolides
- Adverse effects: nausea, vomiting, abdominal pain







Chloramphenicol








Chloramphenicol

- Broad-spectrum
- Mainly --static (but can be --cidal)
- Limited use due to high toxicity
- MOA: *reversibly* to the bacterial 50S ribosomal subunit and inhibits peptidyl transferase reaction
- Given IV: can be secreted in breast milk

Contraindicated in breastfeeding mothers









Chloramphenicol

Adverse effects

- Aplastic anemia, hemolytic anemia in case of G6PD deficiency
- Gray baby syndrome
- -accumulation of the drug due to underdeveloped liver/kidney functions
- -can cause death
- Drug-drug interactions
- -inhibits liver enzymes









Critical Thinking Question

Since chloramphenicol is toxic due to its targeting of the mammalian protein synthesis ... which type of ribosomes in mammalian cells will be most susceptible to inhibition by chloramphenicol? And why?







Clindamycin







Clindamycin

- MOA: same as erythromycin
- Effective against gram-positive bacteria: staph INCLUDING MRSA
- Oral and IV
- Adverse effects: skin rash, diarrhea : associated with pseudomembranous colitis caused by overgrowth of *C. diffcile*
- Treated with vancomycin or metronidazole









Oxazolidinones







Linezolid

- Developed to treat resistant grampositive organisms, such as MRSA (not bacteremia. Why?), VRE, resistant mycobacterium and penicillin-resistant streptococci
- MOA: binds to the bacterial 23S ribosomal RNA of the 50S sub-unit, thereby inhibiting the formation of the 70S initiation complex
- Bacteriostatic (-cidal against strep)

Gram (+) cocci

Enterococcus faecalis (including vancomycin-resistant strains)

Enterococcus faecium (including vancomycin-resistant strains)

<u>Staphylococcus epidermidis</u> (including methicillin-resistant strains)

Staphylococcus aureus (including methicillin-resistant strains)

Staphylococcus haemolyticus

Streptococcus pneumoniae (including penicillin-resistant strains)

Viridans group streptococci

Gram (+) bacilli

<u>Corynebacterium</u> species <u>Listeria monocytogenes</u>

Gram (-) cocci Gram (-) rods

Anaerobic organisms

<u>Clostridium perfringens</u>

Spirochetes Mycoplasma

Chlamydia

Other

Mycobacterium tuberculosis







Linezolid

- Main clinical uses: Treatment of drugresistant gram-positive organisms e.g., alternative to daptomycin for VRE
- Pharmacokinetics: oxidized in the liver into two inactive metabolites → excreted in urine
- Adverse effects: GI upset, thrombocytopenia, serotonin syndrome, peripheral neuropathy (with prolonged use)

Gram (+) cocci	1
Enterococcus faecalis (including vancomycin-resistant strains)
Enterococcus faecium (including vancomycin-resistant strains)
<u>Staphylococcus epidermidis</u> (including methicillin-resistant strains)	
<u>Staphylococcus aureus</u> (including methicillin-resistant strains)	
Staphylococcus haemolyticus	
<u>Streptococcus pneumoniae</u> (including penicillin-resistant strains)	
Viridans group streptococci	
Gram (+) bacilli	
<u>Corynebacterium</u> species <u>Listeria monocytogenes</u>	
Gram (–) cocci Gram (–) rods	
Anaerobic organisms	
Clostridium perfringens	
Spirochetes	
Mycoplasma	
Chlamydia	
Other	
Mycobacterium tuberculosis	

